[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
2. Von Euler HP, Rivera P, Aronsson AC, Bengtsson C, Hansson LO, Eriksson SK: Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay. Int J Oncol; 2009 Feb;34(2):505-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity--evaluation of a new, fully automated non-radiometric assay.
  • Serum TK levels correlate to the proliferative activity of tumor disease.
  • A non-radiometric method based on a competitive immunoassay with specific anti-3'-azido-deoxythymidine monophosphate (AZTMP) antibodies has been further developed into the fully automated Liaison TK assay (DiaSorin).
  • Sera from healthy dogs (n=30), and dogs with leukemia (LEUK) (n=35), ML (n=84), non-hematological tumors (n=50), and inflammatory disease (n=14) were tested using both methods.
  • Lymphoma and LEUK samples were available before and during chemotherapy.
  • The TK1 levels measured during chemotherapy gave very clear differences between dogs in complete remission and dogs out of remission.
  • The Liaison TK assay provides valuable clinical information in the treatment and management of canine LEUK and ML, with a potential to be further validated in human trials.
  • [MeSH-major] Dog Diseases / drug therapy. Leukemia / veterinary. Lymphoma / veterinary. Neoplasms / veterinary
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Cycle. Dogs. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148486.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Yamate J, Kotera T, Kuwamura M, Kotani T: Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines. Exp Toxicol Pathol; 2007 Apr;58(5):299-309
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological modulations in tumor cells treated with anti-cancer drugs have been reported.
  • Immunohistochemically, MT-10 reacted to vimentin, alpha-smooth muscle actin (a marker of myofibroblasts), ED1/ED2 (rat macrophage/histiocyte-specific antibodies), and A3 (rat MFH-specific antibody) in varying degrees, indicating that MFH cells have features of both fibroblasts and histiocytes.
  • MT-10 developed tumors of a storiform pattern, while MT-10R and MT-PR tumors comprise round or polygonal cells arranged in a compact sheet.
  • Additionally, MT-PR tumors included ossifying areas.
  • MT-10R and MT-PR, and their tumors showed a reaction to alkaline phosphatase (ALP), a marker of osteoblasts.
  • RT-PCR revealed that mRNAs of bone morphogenetic protein (BMP)-2, BMP-6 and osteopontin were significantly increased in MT-10R and MT-PR tumors.
  • Neoplastic cells in these tumors were immunoreactive to BMP-2 and BMP-6, while MT-10 tumors were not.
  • Cisplatin-resistant MFH cells had potential to differentiate into osteogenic tissues by producing osteogenic factors, suggesting that MFH histology may be altered under anti-cancer drug treatments.
  • Recently, cancer differentiation-based therapy, that could be induced by anti-cancer drugs, has been implied.
  • MT-10R and MT-PR become useful experimental systems for studies on cellular differentiation provoked by anti-cancer drugs.
  • [MeSH-major] Bone Morphogenetic Proteins / biosynthesis. Cell Differentiation / drug effects. Cisplatin / pharmacology. Drug Resistance, Neoplasm / drug effects. Histiocytoma, Malignant Fibrous / pathology. Osteoblasts / pathology
  • [MeSH-minor] Animals. Bone Morphogenetic Protein 1. Bone Morphogenetic Protein 6. Clone Cells. Enzyme-Linked Immunosorbent Assay. Immunohistochemistry. Metalloendopeptidases / biosynthesis. Neoplasm Transplantation. Osteopontin / biosynthesis. RNA, Messenger / biosynthesis. Rats. Rats, Inbred F344. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267196.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bmp6 protein, rat; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; 106441-73-0 / Osteopontin; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.19 / Bmp1 protein, rat; EC 3.4.24.19 / Bone Morphogenetic Protein 1; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E: Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother; 2006 Jun;55(6):672-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen.
  • Immunization of mice with dendritic cells transfected ex vivo with tumor-associated antigen (TAA)-encoding mRNA primes cytotoxic T lymphocytes (CTL) that mediate tumor rejection.
  • Intradermal and intravenous injection of ovalbumin (OVA) mRNA generated specific CTL activity and inhibited the growth of OVA-expressing tumors.
  • Vaccination studies with DNA have demonstrated that co-administration of antigen (Ag)- and cytokine-encoding plasmids potentiate the T cell response; in analogous fashion, the inclusion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA enhanced OVA-specific cytotoxicity.
  • The ability of this GM-CSF-augmented mRNA vaccine to treat an established spontaneous tumor was evaluated in the Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) mouse, using the SV40 large T Ag (TAg) as a model tumor/self Ag.
  • Repeated vaccination elicited vigorous TAg-specific CTL activity in nontransgenic mice, but tumor-bearing TRAMP mice remained tolerant.
  • Adoptive transfer of naïve splenocytes into TRAMP mice prior to the first vaccination restored TAg reactivity, and slowed tumor progression.
  • Nonetheless, limitations of such vaccines in overcoming tolerance to tumor/self Ag may mandate prior or simultaneous reconstitution of the autoreactive T cell repertoire for this form of immunization to be effective.
  • [MeSH-minor] Animals. Autoantigens / immunology. Disease Models, Animal. Liposomes. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Polymerase Chain Reaction. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / immunology. Transfection

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133108.001).
  • [ISSN] 0340-7004
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA-85307; United States / NCI NIH HHS / CA / R01-CA-89536
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantigens; 0 / Cancer Vaccines; 0 / Liposomes; 0 / RNA, Messenger; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


5. Safe S, McDougal A: Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Int J Oncol; 2002 Jun;20(6):1123-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review).
  • Ligand-activated receptors are extensively used as targets for developing tissue-selective drugs for treatment of multiple diseases including cancers.
  • The high affinity ligand TCDD induces several AhR-mediated changes in gene expression, tissue/species-specific toxicities, and both tumorigenic and anticarcinogenic responses including inhibition of estrogen-dependent mammary and uterine tumor formation and growth.
  • Research in this laboratory has demonstrated that TCDD inhibits E2-induced responses in the rodent uterus and mammary tumors (growth inhibition) and in breast and endometrial cancer cell lines through complex inhibitory AhR-estrogen receptor (ER) crosstalk.
  • These compounds are relatively non-toxic and inhibit ER-positive and ER-negative mammary tumor growth, and synergize with tamoxifen to inhibit breast cancer growth and block tamoxifen-induced estrogenic activity in the uterus.
  • SAhRMs represent a novel class of drugs for treatment of hormone-dependent cancers, and combined therapies of SAhRMs with tamoxifen and other selective ER modulators (SERMs) provides a new approach for treating women with breast cancer.
  • [MeSH-major] Neoplasms, Hormone-Dependent / drug therapy. Receptors, Aryl Hydrocarbon / drug effects
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Female. Humans. Male. Receptors, Estrogen / analysis. Receptors, Estrogen / antagonists & inhibitors. Receptors, Estrogen / drug effects. Selective Estrogen Receptor Modulators / therapeutic use. Tetrachlorodibenzodioxin / pharmacology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12011988.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA64081; United States / NIEHS NIH HHS / ES / ES04176; United States / NIEHS NIH HHS / ES / ES09106
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Aryl Hydrocarbon; 0 / Receptors, Estrogen; 0 / Selective Estrogen Receptor Modulators; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


7. Al-Wadei HA, Schuller HM: Cyclic adenosine monophosphate-dependent cell type-specific modulation of mitogenic signaling by retinoids in normal and neoplastic lung cells. Cancer Detect Prev; 2006;30(5):403-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclic adenosine monophosphate-dependent cell type-specific modulation of mitogenic signaling by retinoids in normal and neoplastic lung cells.
  • The observed stimulation of cAMP/PKA may inhibit the development of small cell lung carcinoma and other tumors derived from large airway epithelia whereas it may selectively promote the development of lung tumors derived from small airway epithelial cells, such as adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ALITRETINOIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):963-71 [15880414.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):35-45 [15949588.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1547-52 [16671086.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):162-8 [10738241.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1563-9 [11313903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Dec;127(12):707-17 [11768610.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):1001-11 [14601062.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):269-76 [14639614.001]
  • [Cites] Lung Cancer. 2004 Jul;45(1):11-8 [15196729.001]
  • [Cites] Curr Opin Pulm Med. 2004 Jul;10(4):279-83 [15220752.001]
  • [Cites] Biochem Pharmacol. 2004 Sep 15;68(6):981-8 [15313391.001]
  • [Cites] J Natl Cancer Inst. 1972 Mar;48(3):743-61 [5058973.001]
  • [Cites] Nature. 1974 Jul 5;250(461):64-6 [4841587.001]
  • [Cites] Fed Proc. 1976 May 1;35(6):1332-8 [770206.001]
  • [Cites] Fed Proc. 1979 Oct;38(11):2528-34 [488376.001]
  • [Cites] Eur J Respir Dis. 1984 Jan;65(1):4-19 [6323208.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1960-5 [2306745.001]
  • [Cites] Adv Exp Med Biol. 1992;320:55-61 [1442284.001]
  • [Cites] Cancer Res. 1993 Nov 15;53(22):5566-8 [8221698.001]
  • [Cites] N Engl J Med. 1994 Apr 14;330(15):1029-35 [8127329.001]
  • [Cites] FEBS Lett. 1994 Apr 11;342(3):286-90 [8150086.001]
  • [Cites] Am Heart J. 1994 Dec;128(6 Pt 2):1316-28 [7977013.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1150-5 [8602180.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1983-90 [8934545.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4898-904 [9354455.001]
  • [Cites] Biochem Pharmacol. 1998 Nov 1;56(9):1229-36 [9802335.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7547-54 [15569985.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1370-80 [16206275.001]
  • (PMID = 17067750.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA088809; United States / NCI NIH HHS / CA / R01 CA096128; United States / NCI NIH HHS / CA / R01-CA088809; United States / NCI NIH HHS / CA / R01-CA096128
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin; E0399OZS9N / Cyclic AMP; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EH28UP18IF / Isotretinoin
  • [Other-IDs] NLM/ NIHMS14425; NLM/ PMC1761122
  •  go-up   go-down


8. Hayashi M, Nishiya H, Chiba T, Endoh D, Kon Y, Okui T: Trientine, a copper-chelating agent, induced apoptosis in murine fibrosarcoma cells in vivo and in vitro. J Vet Med Sci; 2007 Feb;69(2):137-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anti-copper treatments have been investigated to determine whether they suppress angiogenesis and tumor development since Cu is widely accepted as being required for angiogenesis.
  • We examined the effects of treatment with trientine, a copper-chelating agent, on tumor development in a murine xenograft model using fibrosarcoma-derived transplantable QRsp-11 cells and C57BL/6 mice and induction of apoptosis in tumor cells and endothelial cells in vivo and in vitro.
  • The tumor volumes increased more slowly in trientine-treated mice than in untreated mice.
  • Tumor volumes in the treated mice were significantly smaller than those in the untreated mice at 24 days postinoculation (d.p.i.) of tumor cells.
  • A cluster of pyknotic tumor cells and morphological abnormalities in capillary endothelial cells were observed in the tumors of trientine-treated mice but not in the tumors of untreated mice.
  • The proportions of apoptotic and necrotic cells in the tumors of treated mice were approximately 3.5-fold higher than those in the tumors of untreated mice at 14 d.p.i.
  • However, the proportion of apoptotic cells in endothelial cells was significantly lower than that in QRsp-11 cells after treatment with trientine.
  • These results show that apoptosis was induced in tumor cells by treatment with trientine in vivo and in vitro.

  • Hazardous Substances Data Bank. TRIETHYLENETETRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339757.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Chelating Agents; SJ76Y07H5F / Trientine
  •  go-up   go-down


9. Yu KN, Minai-Tehrani A, Chang SH, Hwang SK, Hong SH, Kim JE, Shin JY, Park SJ, Kim JH, Kwon JT, Jiang HL, Kang B, Kim D, Chae CH, Lee KH, Yoon TJ, Beck GR, Cho MH: Aerosol delivery of small hairpin osteopontin blocks pulmonary metastasis of breast cancer in mice. PLoS One; 2010 Dec 22;5(12):e15623
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conventional therapies such as chemotherapy and surgery are somewhat successful, however, metastasis-related breast cancer morbidity remains high.
  • Thus, a novel approach to prevent breast tumor metastasis is needed.
  • Our results showed that noninvasive targeting of pulmonary osteopontin or other specific genes responsible for cancer metastasis could be used as an effective therapeutic regimen for the treatment of metastatic epithelial tumors.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:14 [12605717.001]
  • [Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]
  • [Cites] FASEB J. 1993 Dec;7(15):1475-82 [8262332.001]
  • [Cites] Cancer Res. 1994 Feb 1;54(3):832-7 [8306346.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Ann N Y Acad Sci. 1995 Apr 21;760:299-301 [7785904.001]
  • [Cites] Crit Rev Oncog. 1996;7(3-4):261-91 [9258606.001]
  • [Cites] Invasion Metastasis. 1997;17(1):1-15 [9425320.001]
  • [Cites] Br J Cancer. 1998 Mar;77(6):998-1002 [9528847.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Oral Oncol. 1998 Nov;34(6):543-8 [9930369.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):368-73 [10050871.001]
  • [Cites] J Clin Pathol. 1998 Nov;51(11):798-802 [10193318.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7971-6 [15520204.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R680-8 [15535850.001]
  • [Cites] Zhonghua Gan Zang Bing Za Zhi. 2005 Mar;13(3):227-8 [15760565.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):608-22 [16442099.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 21;98(12):846-55 [16788158.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):1-22 [16767697.001]
  • [Cites] Gene Ther. 2007 Dec;14(24):1721-30 [17960162.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5226-35 [18593923.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2305-18 [18266970.001]
  • [Cites] Am J Respir Crit Care Med. 2009 Jun 15;179(12):1131-40 [19286625.001]
  • [Cites] BMC Gastroenterol. 2009;9:73 [19804649.001]
  • [Cites] Cancer Gene Ther. 2009 Dec;16(12):892-9 [19461674.001]
  • [Cites] Cancer Immunol Immunother. 2010 Mar;59(3):355-66 [19690854.001]
  • [Cites] Curr Mol Med. 2010 Feb;10(1):71-81 [20205680.001]
  • [Cites] Surg Today. 2010 Apr;40(4):347-56 [20339989.001]
  • [Cites] Mol Cancer Ther. 2010 May;9(5):1180-7 [20423989.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Aug;136(8):1283-92 [20157733.001]
  • [Cites] Br J Cancer. 2010 Sep 7;103(6):861-9 [20823889.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2334-40 [10561295.001]
  • [Cites] Gene Ther. 2000 Jan;7(1):20-3 [10680011.001]
  • [Cites] Gene Ther. 2000 Mar;7(6):499-504 [10757023.001]
  • [Cites] Breast Cancer Res Treat. 2000 Feb;59(3):271-8 [10832597.001]
  • [Cites] Mol Med. 2000 Mar;6(3):165-78 [10965493.001]
  • [Cites] Crit Rev Oncog. 2000;11(2):135-46 [11005509.001]
  • [Cites] Nat Med. 2001 Jan;7(1):33-40 [11135613.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):188-200 [11157775.001]
  • [Cites] Oncogene. 2001 Jan 25;20(4):484-9 [11313979.001]
  • [Cites] Mol Ther. 2001 Apr;3(4):551-6 [11319917.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1055-61 [11342566.001]
  • [Cites] Cancer Gene Ther. 2002 Aug;9(8):692-9 [12136431.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):137-41 [12399124.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4368-80 [12409337.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1235-44 [15067347.001]
  • [Cites] Cell Tissue Res. 1989 Apr;256(1):167-73 [2565770.001]
  • (PMID = 21203518.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / R01 AR056090; United States / NCI NIH HHS / CA / R03 CA136059; United States / NIAMS NIH HHS / AR / AR056090; United States / NCI NIH HHS / CA / CA136059
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aerosols; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC3008732
  •  go-up   go-down


10. Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW, Waters DJ: Influence of host factors on survival in dogs with malignant mammary gland tumors. J Vet Intern Med; 2003 Jan-Feb;17(1):102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of host factors on survival in dogs with malignant mammary gland tumors.
  • The purpose of our study was to determine if specific host factors, such as age at diagnosis, obesity, and hormone status, influence the prognosis of canine mammary gland carcinomas and to confirm if previously reported risk factors (ie, histologic subtype, tumor size, and World Health Organization [WHO] stage) were important in a large series of affected dogs.
  • Ninety-nine female dogs with mammary gland carcinomas, no previous therapy, an excisional biopsy, and known cause of death were studied.
  • No significant association with survival was noted for age at diagnosis (chronologic or physiologic), obesity, or hormone status (ie, spayed versus intact, regardless of time of being spayed).
  • Of the tumor factors analyzed, the histologic subtype anaplastic carcinoma (P = .02), WHO stage I (P = .01), evidence of metastasis at the time of diagnosis (P = .004), and tumor size of 3 cm or smaller (P = .005) all significantly influenced survival.
  • Dogs that were classified as having tumor-related mortality had a shorter postoperative survival compared to dogs that died of other causes (14 months versus 23 months; P = .03).
  • In conclusion, histologic subtype, WHO stage, and tumor size remain important prognostic factors in canine mammary gland tumors.
  • Further study of other prognostic factors is needed to determine which tumors are adequately addressed with local therapy only and which dogs may require adjuvant treatment with chemotherapy.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12564734.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  •  go-up   go-down


11. Bergman PJ: Clinical techniques in small animal molecular oncology. Clin Tech Small Anim Pract; 2003 May;18(2):88-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical techniques in small animal molecular oncology.
  • The diagnosis, staging, and treatment of tumors in veterinary as well as human oncology have traditionally incorporated elements of anatomic extent of neoplasia through various clinical and pathologic methods.
  • These clinicopathological methods have been the basis for the development of the tumor, node, and metastasis and grading systems, which have translated into clinically significant advances over the last 20 to 30 years.
  • Unfortunately, there continues to be significant limitations to this system when prognostication and therapeutic decisions need to be made specific to a patient.
  • For example, completely resected and cleanly staged phenotypically identical grade II mast cell tumors in dogs can have opposing clinical outcomes.
  • In addition, dogs or cats with identical stage and grade lymphoma can have significantly divergent responses to the same multi-agent chemotherapy protocol.
  • Numerous nonanatomic neoplastic molecular prognostic factors have been recently identified and have the potential to improve on the presently available tumor, node, and metastasis- and grading-based systems.
  • This review will summarize how to best utilize presently available tumor, node, and metastasis- and grading-based systems, and incorporate newly available molecular prognostic factors.
  • [MeSH-major] Dog Diseases / pathology. Neoplasms / veterinary
  • [MeSH-minor] Animals. Biomarkers, Tumor. Dogs. Immunohistochemistry / veterinary. Neoplasm Invasiveness. Veterinary Medicine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12831067.001).
  • [ISSN] 1096-2867
  • [Journal-full-title] Clinical techniques in small animal practice
  • [ISO-abbreviation] Clin Tech Small Anim Pract
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 15
  •  go-up   go-down


12. Ferreira AJ, Jaggy A, Varejão AP, Ferreira ML, Correia JM, Mulas JM, Almeida O, Oliveira P, Prada J: Brain and ocular metastases from a transmissible venereal tumour in a dog. J Small Anim Pract; 2000 Apr;41(4):165-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain and ocular metastases from a transmissible venereal tumour in a dog.
  • A presumptive diagnosis of transmissible venereal tumour (TVT) and iridocyclitis was made based on the results of fine needle aspiration.
  • Chemotherapy with vincristine and prednisolone was initiated and after four months the dog made a complete recovery.
  • In addition, the dog exhibited generalised 'grand mal' type seizures.
  • On histopathology, metastases of TVT in the left eye and left cerebral hemisphere were found, showing no specific staining for CD3, immunoglobulin (Ig) G, IgM and lambda light chains.
  • It was therefore concluded that the tumour growth was progressive, and that there was an absence of local humoral immune response against TVT in this case.
  • [MeSH-major] Brain Neoplasms / veterinary. Dog Diseases / pathology. Eye Neoplasms / veterinary. Venereal Tumors, Veterinary / pathology
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dogs. Male. Seizures / veterinary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10812546.001).
  • [ISSN] 0022-4510
  • [Journal-full-title] The Journal of small animal practice
  • [ISO-abbreviation] J Small Anim Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


13. Bauer JA, Frye G, Bahr A, Gieg J, Brofman P: Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs. Invest New Drugs; 2010 Oct;28(5):694-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs.
  • PURPOSE: Given the limited options available to treat canine cancers, the use of companion animals for evaluating new drugs may identify better therapies for veterinary and human oncology.
  • The anti-tumor effects of nitrosylcobalamin (NO-Cbl), an apoptosis-inducing, vitamin B12-based carrier of nitric oxide (NO), was evaluated in four dogs with spontaneous cancer.
  • (1) A 13 year-old female spayed Giant Schnauzer with inoperable thyroid carcinoma and hypercalcemia. (2) A 6 year-old male neutered Golden Retriever with a malignant peripheral nerve sheath tumor (MPNST). (3) A ten yr-old neutered male Bichon Frise with apocrine gland anal sac adenocarcinoma (AGACA). (4) A 7 year-old female spayed Labrador mix with spinal meningioma following partial surgical resection.
  • Tumor regression was measured by physical exam and verified using ultrasound (case 1) and MRI (case 2-4).
  • (1) The Giant Schnauzer demonstrated a 77% reduction in tumor volume after ten weeks of daily NO-Cbl treatment. (2) The Golden Retriever demonstrated a 53% reduction in tumor volume after 15 months of daily NO-Cbl therapy. (3) The Bichon Frise demonstrated a 43% regression of the primary tumor and a 90% regression of an iliac lymph node measured by MRI after 15 months of treatment.
  • After 61 months, the dog currently has stable disease, normal liver enzymes, CBC analysis, and no evidence of toxicity. (4) The Labrador demonstrated complete regression of the residual tumor after 6 months of treatment.
  • The use of NO-Cbl capitalizes on the tumor-specific properties of the vitamin B12 receptor and represents a promising anti-cancer therapy.
  • [MeSH-major] Dog Diseases / drug therapy. Neoplasms / veterinary. Nitroso Compounds / therapeutic use. Vitamin B 12 / analogs & derivatives
  • [MeSH-minor] Animals. Antineoplastic Agents / metabolism. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Dogs. Dose-Response Relationship, Drug. Female. Magnetic Resonance Imaging. Male. Tumor Burden. Ultrasonography

  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2011 Oct;29(5):1122
  • [Cites] Eur J Cancer. 2004 Apr;40(6):858-80 [15120042.001]
  • [Cites] J Vet Intern Med. 1988 Jan-Mar;2(1):41-6 [3221354.001]
  • [Cites] Nat Med. 2005 Oct;11(10):1018 [16211022.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):181-93 [15354401.001]
  • [Cites] J Am Vet Med Assoc. 1991 May 1;198(9):1618-21 [2061177.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Jan-Feb;34(1):19-25 [9527425.001]
  • [Cites] Vet Radiol Ultrasound. 2001 Sep-Oct;42(5):471-4 [11678572.001]
  • [Cites] J Small Anim Pract. 1999 May;40(5):206-10 [10385862.001]
  • [Cites] J Am Vet Med Assoc. 2006 Aug 15;229(4):542-8 [16910854.001]
  • [Cites] J Vet Intern Med. 2002 Jan-Feb;16(1):100-4 [11822797.001]
  • [Cites] Clin Tech Small Anim Pract. 2007 May;22(2):75-81 [17591293.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Jul;4(2):112-28 [16102268.001]
  • [Cites] Anticancer Drugs. 1998 Mar;9(3):239-44 [9625434.001]
  • [Cites] J Nucl Med. 1997 May;38(5):717-23 [9170435.001]
  • [Cites] Semin Vet Med Surg (Small Anim). 1996 Nov;11(4):225-34 [9020576.001]
  • [Cites] Aust Vet J. 2005 Jun;83(6):340-3 [15986909.001]
  • [Cites] Cancer Invest. 2000;18(8):781-92 [11107448.001]
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):568-80 [10852417.001]
  • [Cites] J Am Vet Med Assoc. 1975 Mar 1;166(5):511-7 [1112759.001]
  • [Cites] Aust Vet J. 2005 Apr;83(4):208-14 [15907038.001]
  • [Cites] J Am Anim Hosp Assoc. 1998 Mar-Apr;34(2):109-12 [9507422.001]
  • [Cites] Vet Pathol. 2004 Jul;41(4):307-18 [15232130.001]
  • [Cites] J Am Anim Hosp Assoc. 1997 Jul-Aug;33(4):307-12 [9204465.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):1010-9 [12096086.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):420-30 [12189384.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39461-9 [12881518.001]
  • [Cites] J Am Vet Med Assoc. 1995 Apr 1;206(7):1007-9 [7768706.001]
  • [Cites] J Am Vet Med Assoc. 2003 Sep 15;223(6):825-31 [14507100.001]
  • [Cites] J Clin Invest. 1999 Jul;104(2):155-62 [10411544.001]
  • [Cites] J Vet Intern Med. 1994 May-Jun;8(3):236-9 [8064663.001]
  • [Cites] J Am Anim Hosp Assoc. 1995 Jul-Aug;31(4):349-59 [7552669.001]
  • [Cites] In Vivo. 1994 Jan-Feb;8(1):133-43 [8054503.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5588-94 [16847314.001]
  • [Cites] J Am Vet Med Assoc. 1989 Dec 1;195(11):1580-3 [2599941.001]
  • [Cites] Vet Comp Oncol. 2003 Jun;1(2):94-104 [19379321.001]
  • [Cites] J Neurosurg Anesthesiol. 1994 Apr;6(2):111-5 [8012169.001]
  • [Cites] J Small Anim Pract. 1981 Mar;22(3):119-28 [7230749.001]
  • [Cites] Vet Surg. 2006 Apr;35(3):267-70 [16635006.001]
  • [Cites] Vet Pathol. 1998 May;35(3):223-6 [9598587.001]
  • [Cites] PLoS One. 2007 Dec 12;2(12):e1313 [18074035.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Mar;25(1):97-105 [16761625.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):161-2 [16449674.001]
  • [Cites] J Am Vet Med Assoc. 1987 Sep 15;191(6):720-6 [3679964.001]
  • (PMID = 19557306.001).
  • [ISSN] 1573-0646
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Nitroso Compounds; 0 / nitrosylcobalamin; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down






Advertisement